Por: The Boston Globe Business August 03, 2023
Moderna raised its COVID-19 vaccine sales outlook for the year, finalizing contracts with Japan and several American health care companies as the US government largely stops paying for the shots.Moderna now sees sales of $6 billion to $8 billion, according to a statement Thursday, up from a previous prediction of at least $5 billion and in line with the analysts’ average estimate of $6.9 billion. The Cambridge-based company is in talks with... + full article
Portland Press Herald USA World September 13, 2023
Moderna said a reformulated version of its messenger-RNA-based flu shot met its primary goals in a final-stage trial – a result that could pave the way for the company to seek regulatory approval for the influenza vaccine. In a trial on over 2,400 adults, the reformulated shot... + más
Moderna Stock Futures: Is COVID Vaccine Maker Moderna Poised To Pop Or Drop? | Forbes
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
The Boston Globe USA Business June 23, 2023
Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.Basking in the accolades heaped on Moderna’s celebrated COVID-19 vaccine, Afeyan regaled the Boston audience with the company’s... + más
High school scores and top performers from Friday, March 24 | Orlando Sentinel
Fox Business USA Business March 11, 2023
Check out what's clicking on FoxBusiness.com has revealed it will add to its workforce and its U.S. office footprint. In a put out Friday, Moderna said it will add about 2,000 new employees around the world.Moderna’s hiring efforts seemingly contrast with the reductions... + más
Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim. | MarketWatch
MarketWatch USA Business February 28, 2023
The earnings announcement was a sort of rubber-hits-the-road moment for Moderna (ticker: MRNA), as investors, who have been generally anticipating a drop in Covid-19 vaccine sales ever since the jab first was authorized late 2020, for the first time could fully reckon what it... + más
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
Forbes USA Business November 29, 2022
Getty Images Key Takeaways Moderna became a household name for creating one of the first COVID-19 vaccines, helping to loosen up pandemic restrictions globally. Moderna’s stock went up during the pandemic for apparent reasons as countries were scrambling to purchase mass... + más
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |